The helicase-primase complex as a target for effective herpesvirus antivirals

Advances in Experimental Medicine and Biology

Volumn 767, Issue , 2013, Pages 145-159

  Field, Hugh J ^a   Mickleburgh, Ian ^b  

^a QUEENS COLLEGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AIC 316; AMENAMEVIR; ANTIVIRUS AGENT; BAY 57 1293; BILS 179 BS; BILS 45 BS; DNA PRIMASE; ENZYME INHIBITOR; FAMCICLOVIR; GANCICLOVIR; HELICASE; IDOXURIDINE; PENCICLOVIR; PLACEBO; T 157602; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; DNA HELICASE; VIRUS PROTEIN; ANTIINFECTIVE AGENT; THIOZOLYL PHENYL DERIVATIVE; UL5 PROTEIN; UL52 PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CHICKENPOX; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; GENE MUTATION; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION; GENETICS; HERPESVIRIDAE; ABSENCE OF SIDE EFFECTS; ARTICLE; CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COMPLEX FORMATION; CONCENTRATION RESPONSE; CROSS RESISTANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; GENE INTERACTION; HERPES SIMPLEX VIRUS 2; HISTORY OF MEDICINE; IC 50; INFECTION PREVENTION; INFECTION RATE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UL5 GENE; UL52 GENE; VIRUS GENE; VIRUS LATENCY; VIRUS TRANSMISSION;

HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

ANTIVIRAL AGENTS; DNA HELICASES; DNA PRIMASE; HERPESVIRIDAE; HERPESVIRUS 1, HUMAN; HUMANS; VIRAL PROTEINS;

EID: 84873648615     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5037-5_7     Document Type: Review

References (42)

1. Field HJ, De Clercq E. Antiviral drugs: a short history of their discovery and development. Microbiol Today. 2004;31:58-61.
2. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006;147:1-11.
3. Harmenberg JG, Awan AR, Alenius S, Stahle L, Erlandsson AC, Lekare G, et al. ME-609: a treatment for recurrent herpes simplex virus infections. Antivir Chem Chemother. 2003;14:205-15.
4. Crute JJ, Tsurumi T, Zhu L, Weller SK, Olivo PD, Challberg MD, et al. Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products. Proc Natl Acad Sci USA. 1989;86:2186-9.
5. Spector FC, Liang L, Giordano H, Sivaraja M, Peterson MG. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol. 1998;72:6979-87.
6. Zhu L, Weller SK. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function. J Virol. 1992;66:469-79.
7. Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher A-M, Bolger G, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med. 2002;8:386-91.
8. Duan J, Liuzzi M, Paris W, Liard F, Browne A, Dansereau N, et al. Oral bioavailability and in vivo ef fi cacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother. 2003;47:1798-804.
9. Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med. 2002;8:392-8.
10. Kleymann G. New antiviral drugs against herpesviruses. Herpes. 2003;10:46-52.
11. Betz UAK, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY57-1293. Antimicrob Agents Chemother. 2002;4:1766-72.
12. Anderson JR, Field HJ. The distribution of herpes simplex type 1 antigen in mouse central nervous system after different routes of inoculation. J Neurol Sci. 1983;60:181-95.
13. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior ef fi cacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother. 2007;18:35-48.
14. Harmenberg J, Abele G, Malm M. Deoxythymidine pools in animal and human skin with reference to antiviral drugs. Arch Dermatol Res. 1985;277:402-3.
15. Harmenberg J, Abele G, Wahren B. Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells. Antiviral Res. 1985;5:75-81.
16. Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 2007;75:30-5.
17. Birkmann A, Hewlett G, Rubsamen-Schaeff H, Zimmermann H. Helicase primase inhibitors as the potential next gerneration of highly active drugs against herpes simplex viruses. Future Virol. 2011;6:1199-209.
18. Birkman A, Kropeit D, Biswas S, Paulsen D, Sukla S, Field HJ. PK/PD evaluation of AIC316, a novel herpes simplex virus inhibitor currently in clinical development. Presented at Antivirals congress, Amsterdam, The Netherlands; 7-9 Nov 2010.
19. Wald A, Stoellben S, Tyring S, Warren T, Johnston C, Huang M-L, et al. Impact of AIC316, a novel antiviral helicase-primase inhibitor, on genital HSV shedding: randomized, double-blind, placebo-controlled trial. Presented at 19th Biennial conference of the International Society of Sexually Transmitted Diseases Research (ISSTDR) Quebec City, QC, Canada; 10-13 July 2011.
20. Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokota T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65:1733-41.
21. Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokata T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65:1733-41.
22. Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes. Molecules. 2011;16:7210-23.
23. ClinicalTrials.gov. Dose- fi nding study of ASP2151 in subjects with herpes zoster. http://clinicaltrials. gov/ct2/show/NCT00487682
24. ClinicalTrials.gov. A study with ASP2151 in subjects with recurrent episodes of genital herpes. http://clinicaltrials.gov/ct2/show/NCT00486200.
25. Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol. 2001;21:261-9.
26. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-28.
27. Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982;22:71-7.
28. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Antiviral Res. 2002;5:88-114.
29. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother. 1998;42:868-72.
30. Christophers J, Sutton RN. Characterization of acyclovir-resistant and sensitive clinical isolates of herpes simplex virus isolates from an immunocompromised patient. J Antimicrob Chemother. 1987;20:389-98.
31. Liuzzi M, Kibler P, Bousquet C, Harji F, Bolger G, Garneau M, et al. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res. 2004;64:161-70.
32. Field HJ, Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist Updat. 2011;14:45-51.
33. Biswas S, Field HJ. Helicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella-zoster virus. In: De Clercq E, editor. Antiviral drug strategies. Weinheim: Wiley; 2011. p. 129-45.
34. Biswas S, Swift M, Field HJ. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir Chem Chemother. 2007;18:13-23.
35. Biswas S, Smith C, Field HJ. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1. J Antimicrob Chemother. 2007;60:274-9.
36. Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field H. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. J Antimicrob Chemother. 2010;65:1347-52.
37. Sukla S, Biswas S, Birkmann A, Lischka P, Ruebsamen-Schaeff H, Zimmermann H, et al. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Res. 2010;87:67-73.
38. Biswas S, Jennens L, Field HJ. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch Virol. 2007;152:1489-500.
39. Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 2008;80:81-5.
40. Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre- Hernández J, et al. A single drugresistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J Antimicrob Chemother. 2008;61:1044-7.
41. Field HJ, Mickelburgh I, Huang M-L, Tiley L, Wald A, Ruebsamen-Schaeff H, et al. Sensitivity of Clinical isolates to helicase primase inhibitors and no detection of resistance mutations above background frequency. In: Twenty fi fth international conference on antiviral research, Sapporo, Japan; 2012, Abstract 46.
42. Biswas S, Miguel RN, Sukla S, Field HJ. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J Gen Virol. 2009;90:1937-42.